Menu
News
Ibogaine
Ketamine
LSD
MDMA
Psilocybin
Resources
Research Hubs
Studies and Reports
Provider Directory
Terminology
Opinion
Events
About Us
FDA
Cybin: CYB003 Achieves ‘Primary Efficacy Endpoint’ in Phase 2 Study
December
1
,
2023
Veterans Subcommittee Hearing Highlights Potential of MDMA, Psilocybin Therapy
November
19
,
2023
FDA: At-Home Ketamine Treatments Pose Serious Risks, Lack Supervision
November
14
,
2023
1
2
3